surmount-1 trial tirzepatide weight loss nondiabetic SURMOUNT-1: In an RCT, adults with obesity treated with weekly had major over 72 weeks. #ADA2022 https://t.co/X2RrvYxzsV Tirzepatide Delivers in SURMOUNT-2 -

Compound movements (squats, deadlifts, rows, presses) are most effective

Its use in treating obesity by affecting appetite and food intake leads to substantial weight loss, with implications for weight maintenance upon discontinuation

That extra glucagon-receptor activation may increase energy expenditure, enhance fat oxidation, and produce a stronger metabolic effect than dual-agonist medications

If you added 3 mL instead of 2 mL to a 10 mg vial, your concentration is 3.33 mg/mL instead of 5 mg/mL

study of over 18,000 patients found tirzepatide users lost approximately 15.3% of body weight at 12 months compared to 8.3% with semaglutide